Jade Biosciences, Inc. (JBIO)
NasdaqCM · USD · Healthcare · Biotechnology
$14.74 (+1.66%) as of
Key statistics
- Market cap
- 937.43M
- Forward P/E
- -5.54
- EPS (TTM)
- -1.92
- Dividend yield
- 0.00%
- 52-week range
- 8.36 – 28.00
- Profit margin
- 0.00%
- Analyst target
- $50.13
- Volume
- 652.89k
About Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Waltham, MA, United States
- Employees
- 55
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.